Senti Biosciences(SNTI) - 2024 Q2 - Quarterly Results

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights – Dose Finding Ongoing in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML – – Commencement of $8 Million Grant Award from CIRM for the Clinical Development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., August 13, 2024 -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation ce ...